April 16 (Reuters) - HERANTIS PHARMA OYJ:
* REG-HERANTIS PHARMA ANNOUNCES POSITIVE INTERIM DATA FROM LYMFACTIN STUDY IN SECONDARY LYMPHEDEMA
* PHASE 1 STUDY CONTINUES WITH A 12-MONTH FOLLOW-UP ON PATIENTS. Source text for Eikon: Further company coverage: (Gdynia Newsroom)